Keywords
troponin
creatine phosphokinase MB
How to Cite
Abstract
Introduction: Creatine phosphokinase MB isoenzyme (CK-MB) has been used as a marker of myocardial infarction (MI) for several decades. Its use is currently recommended only in cases where the laboratory does not have troponin, since it does not provide additional information and generates unnecessary costs. Objectives: To evaluate the Sensitivity (S), Specificity (E), Positive Predictive Value (PPV), and Negative Predictive Value (NPV) of high-sensitivity troponin I (hs-cTnI) and CK-MB activity in patients with suspected MI and a subpopulation of patients with normal hs-cTnI values. Materials and methods: A total of 230 patients attended in an Emergency Department with requests for hs-cTnI with or without the addition of CK-MB during July 2021 were retrospectively studied. Results: The mean age was 54 years (24 - 84 CI: 95%), and 120 were men (52%) and 110 women (48%). Of the total, 21 patients (9.1%) were diagnosed with MI. The values of S, E, PPV, and PPV for hs-cTnI were 95.4%, 86.5%, 42.8%, and 99.4%, respectively, whereas the values for CK-MB activity were 70.5%, 64.2%, 17.9% and 95.1% respectively for the general population, and 0%, 71%, 0% and 98.7% for the subpopulation with normal hs-cTnI. Conclusion: CK-MB activity does not provide more information than that already provided by troponin and has zero S and VVP when associated with normal hs-cTnI values.
References
Sociedad Argentina de Cardiología. Consenso para el manejo de pacientes con síndrome coronario agudo sin supradesnivel del segmento ST (angina inestable e infarto de miocardio sin elevación del st). Rev Argent Cardiol 2014;82(1): 1-44.
Apple FS, Jaffe AS, Collinson P, Mockel M, Ordonez-Llanos J, LindahlB, et al. IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. ClinBiochem 2015; 48:201-3.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al. Fourth universal definition of myocardial infarction (2018). European heart journal 2019; 40(3): 237-69.
Sanchis J, Alquézar-Arbé A, Ordóñez-Llanos J, Bardají A. La troponina cardiaca de alta sensibilidad en la evaluación del paciente con sospecha de SCA: ¿verdadera o falsa amiga? Rev Esp Cardiol 2019; 72(6): 445-8.
Jaffe AS, Ordonez-Llanos J. Troponina cardiaca ultrasensible: de la teoría a la práctica clínica. Rev Esp Cardiol 2013; 66(9): 687-91.
Bono JOE, Barcudi R, Sarmiento PE. Utilidad de las troponinas para el manejo del paciente crítico con enfermedad no cardíaca en la Unidad de Cuidados Intensivos.: Revisión narrativa. Rev Arg de Ter Int. 2020;37(3): 43-57.
Ramos H, Bono J, Macín S, Muntaner J, Zapata G, Zoni R, et al. Documento de consenso sozre el uso de Troponinas cardíacas en pacientes con dolor torácico agudo del Comité de Cardiopatía Isquémica de la Federación Argentina de Cardiología. Rev Fed Arg Cardiol 2020; 49: 04-23.
Calmarza P, Vazquez Gil J. Sobrestimación de la CK-MB obtenida por inmunoinhibición debido a la presencia de Macro-CK tipo I. Rev Electron Biomed [Internet]. 2004 [citado 6 Jun 2022]; 1:63-7. Disponible en: https://biomed.uninet.edu/2004/n1/calmarza.html
Santaló M, Guindo J, Ordoñez J. 2003. Marcadores biológicos de necrosis miocárdica. Rev. Esp Cardiol 2003; 56(7): 703-20.
Volz KA, McGillicuddy DC, Horowitz GL, Sanchez LD. Creatine kinase-MB does not add additional benefit to a negative troponin in the evaluation of chest pain. Am J Emerg Med 2012;30(1): 188-90.
Singh G, Baweja PS. Creatine kinase-MB: The Journey to Obsolescence. Am J Clin Pathol 2014; 141(3): 415-9.
Le RD, Kosowsky JM, Landman AB, Bixho I, Melanson S, Tanasijevic MJ. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med 2015; 33(1):72-75.